Observational study on Epithelioid Sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective national study in Italy aims to describe the population affected by Epithelioid Sarcoma (ES) and provide insights into the natural history of the disease. It will address outstanding questions regarding the management of ES and focus on the differences between its two variants: classical-type and proximal-type. The goal is to enhance understanding of the disease, tailor treatment approaches, and ultimately improve patient outcomes.

Why it matters

Who can join: the full rules

Inclusion criteria

1. Histological diagnosis of epithelioid sarcoma according to 2014 World Health Organization (WHO) classification, performed on biopsy or surgical specimen
2. Signed informed consent
3. Adequate patient compliance to treatment or follow up
4. No age limit

Exclusion criteria

1. Other malignancies within past 5 years, with exception of carcinoma in situ of the cervix and basocellular skin cancers treated with eradicating intent
2. Impossibility to ensure adequate compliance

Where it's running

• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori - IRST
  Meldola, Fc, Italy Recruiting
• Istituto Europeo di Oncologia
  Milan, Mi, Italy Recruiting
• Istituto Clinico Humanitas
  Rozzano, Mi, Italy Recruiting
• Azienda Ospedaliera Universitaria Paolo Giaccone
  Palermo, PA, Italy Recruiting
• Fondazione del Piemonte per l'Oncologia IRCC Candiolo
  Candiolo, Torino, Italy Recruiting
• Istituto Ortopedico Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors
  Bologna, Italy Recruiting

Study contacts

• Principal investigator: Paolo Casali, MD — Fondazione IRCCS INT Milano
• Study coordinator: Annamaria Frezza, MD
• Email: annamaria.frezza@istitutotumori.mi.it
• Phone: 003902390

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Alpha/beta T‑Cell and B‑Cell Depletion plus Zoledronic Acid for Pediatric and Young Adult Solid Tumors

  This study will try removing alpha/beta T cells and B cells from donor stem cell grafts and giving zoledronic acid to see if it helps children and young adults (6 months to 25 years) with relapsed or high‑risk solid tumors tolerate allogeneic transplant and reduce relapse.

  Recruiting Phase 1/2 University of Florida · Gainesville, Florida · NCT06625190

• MASCT-I plus doxorubicin and ifosfamide as first-line treatment for advanced soft tissue sarcoma

  This trial will test whether adding MASCT-I to standard chemotherapy (doxorubicin and ifosfamide) helps adults with advanced soft tissue sarcoma respond better or live longer.

  Recruiting Phase 2 HRYZ Biotech Co. · Guangzhou · NCT06277154

• Evaluating treatments for non-rhabdomyosarcoma soft tissue sarcoma in young patients

  This study is testing a combination of chemotherapy and radiation to see if it helps young patients with non-rhabdomyosarcoma soft tissue sarcoma live longer without their cancer coming back.

  Recruiting at 7 sites Phase 1/2 St. Jude Children's Research Hospital · Atlanta, Georgia and 6 other locations · NCT06239272

• Evaluating a new oral medication for certain types of cancer

  This study is testing a new oral medication for people with certain types of lymphoma and advanced solid tumors to see how safe it is and if it helps them.

  Recruiting at 21 sites Phase 1/2 Haihe Biopharma Co., Ltd. · Phoenix, Arizona and 24 other locations · NCT04390737

• Characterizing rare soft tissue sarcomas

  This study is trying to learn more about rare types of soft tissue sarcomas by collecting detailed information from 400 patients to help improve treatment options.

  Recruiting at 16 sites Institut Claudius Regaud · Besançon and 19 other locations · NCT03967834

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.